• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,138
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 119
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,017
1,203
1,882
2,986

PUBLISHED

15
208
647
2,986

PRODUCT TYPE

2,412
494
70
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014 Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2014

Aberrant activation of the Hedgehog pathway has been associated with a number of human malignancies including carcinoma of lung, esophagus, pancreas and prostate. There are today 119 companies plus...

July 2014
FROM
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014

Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified...

July 2014
FROM
Pancreatic Cancer Drug Pathway Analyzer 2014 Pancreatic Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Pancreatic Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 294 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways...

July 2014
FROM
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-3 signaling pathway activates the JAK/STAT, MAPK and PI 3-kinase signaling modules. There are today 184 companies plus partners developing 261 IL-3 pathway targeting drugs in 971 developmental...

July 2014
FROM
Lung Cancer Drug Pathway Analyzer 2014 Lung Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Lung Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 487 targeted molecular therapies known to affect more than 254 specific intracellular signaling pathways...

July 2014
FROM
Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Nucleic Acid Therapies in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 285 nucleic acid drugs known to affect more than 223 specific intracellular signaling pathways for the...

July 2014
FROM
Ovarian Cancer Drug Pipeline Update 2014 Ovarian Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Update 2014

With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for...

July 2014
FROM
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-5 singaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 124 companies plus partners developing 167 IL-5 pathway targeting drugs in 667 developmental projects...

July 2014
FROM
Proteins in Oncology Drug Pipeline Update 2014 Proteins in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Proteins in Oncology Drug Pipeline Update 2014

This drug pipeline update covers proteins, excluding antibodies, as drugs for the treatment of cancer. There are today 326 companies plus partners developing 359 protein drugs in 667 developmental projects...

July 2014
FROM
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-6 signaling pathway activates the Jak/STAT, Ras/Raf/MAPK and PI 3-kinase signaling modules. There are today 261 companies plus partners developing 362 IL-6 pathway targeting drugs in 1210 developmental...

July 2014
FROM
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The Kit receptor signaling pathway includes activation of PI 3-kinase, Src family kinases and PLC gamma. Activating mutations in the Kit receptor are associated with several human malignancies include...

July 2014
FROM
Radiation Therapy in Oncology Drug Pipeline Update 2014 Radiation Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Radiation Therapy in Oncology Drug Pipeline Update 2014

This drug pipeline update is structured around radiolabeled drugs, radiosensitizers and radioprotective compounds. There are today 318 companies plus partners developing 333 radiation therapy drugs...

July 2014
FROM
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-1 signaling pathway activates the MAPK/JNK signaling modules. The MAPK pathway leads to activation of NFkB complex. As both IL-1 and TNF alpha stimulate the MAPK signaling module and activate...

July 2014
FROM
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014

Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors of breast, colon, pancreas, liver and bone. There are today 179 companies plus partners...

July 2014
FROM
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-9 signaling pathway activates Jak/STAT and MAPK signaling modules. There are today 63 companies plus partners developing 67 IL-9 pathway targeting drugs in 275 developmental projects in cancer....

July 2014
FROM
Oncology Drug Pathway Analyzer (Standard Version) Oncology Drug Pathway Analyzer (Standard Version) - Product Thumbnail Image

Oncology Drug Pathway Analyzer (Standard Version)

EXTRA: Free online updates for a year Get instant, interactive pathway modeling on more than 3,500 cancer drugs across more than 100 different cancer types. Drug targets and their pathways are the...

July 2014
FROM
Leukemia Drug Pipeline Update 2014 Leukemia Drug Pipeline Update 2014 - Product Thumbnail Image

Leukemia Drug Pipeline Update 2014

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today 292 companies plus partners developing 417 leukemia drugs in 632 developmental...

July 2014
FROM
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014 Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014

The binding of Leptin to its receptor, LEPR induces various signaling modules such as JAK/STAT, RAS/RAF/MAPK, IRS/PI-3K and AMPK/ACC. There are today 271 companies plus partners developing 392 Leptin...

July 2014
FROM
Cancer Stem Cells Drug Pipeline Update 2014 Cancer Stem Cells Drug Pipeline Update 2014 - Product Thumbnail Image

Cancer Stem Cells Drug Pipeline Update 2014

Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs...

July 2014
FROM
Brain Cancer Drug Pipeline Update 2014 Brain Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Brain Cancer Drug Pipeline Update 2014

Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos